PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

Sickle Cell Disease Clinical Trial

— HESTIA4  

Official title:

A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03492931
• Other study ID #: D5136C00010
• Status: Completed
• Phase: Phase 1
• Start date: March 28, 2018
• Est. completion date: May 7, 2019

Study information

• Verified date: May 2021
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase I study is to investigate the pharmacokinetic properties of ticagrelor in pediatric patients from 0 to less than 24 months with sickle cell disease.

Ticagrelor dose level adjustment will require a Protocol amendment and regulatory approval.

Description:

Study design This Phase I paediatric study (in patients aged 0 to <24 months) with ticagrelor is planned to be a multi-centre, open-label, single dose study.

Primary Objective:

To determine the PK properties of ticagrelor after a single oral dose

Secondary Objectives:

To determine the PK properties of the active metabolite (AR-C124910XX) after a single oral dose To assess the acceptability and the palatability of a single oral dose of ticagrelor

Safety Objective:

To assess safety and tolerability of a single oral dose of ticagrelor

Duration of treatment At least 20 eligible patients will receive a single open label oral dose of ticagrelor on Day 1.

Statistical methods A population PK analysis approach will be used to determine the PK parameters of ticagrelor and its metabolite AR-C124910XX in paediatric patients aged 0 to <24 months eg, CL/F (oral clearance) (only for ticagrelor) and AUC.

The PK will also be described by presenting the observed plasma concentrations of Ticagrelor and its active metabolite for all individuals, as well as corresponding descriptive statistics.

No statistical comparisons are planned for the primary or secondary objectives, which will be summarised descriptively

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 7, 2019
• Est. primary completion date: May 7, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 23 Months

Eligibility

Inclusion Criteria:

1. Paediatric patients aged <24 months, diagnosed with homozygous sickle cell (HbSS) or sickle beta-zero-thalassemia (HbS/ß0), as confirmed by high performance liquid chromatography or haemoglobin electrophoresis.

2. Body weight =5 kg at the time of screening.

3. If treated with an anti-sickling agent such as hydroxyurea, the weight-adjusted dose must be stable for 3 months before screening/enrolment.

4. Provision of signed and dated written informed consent from parents/legal guardians prior to any study specific procedures not part of standard medical care.

Exclusion criteria

1. History of transient ischaemic attack or cerebrovascular event/accident (ischaemic or haemorrhagic), severe head trauma, intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or proliferative retinopathy.

2. Significantly underdeveloped with regards to height, weight or head circumference for age, as judged by the Investigator.

3. Severe developmental delay (eg, cerebral palsy or mental retardation).

4. Receiving chronic treatment (>3 days/week) with non-steroidal anti-inflammatory drugs (NSAIDs).

5. Receiving chronic treatment with anticoagulants or antiplatelet drugs that cannot be discontinued.

6. Moderate or severe hepatic impairment, defined as laboratory values of alanine aminotransferase (ALT) >2 × upper limit of normal (ULN), total bilirubin >2 × ULN (unless judged by the Investigator to be caused by haemolysis), albumin <35 g/L and international normalised ratio (INR) >1.4, or symptoms of liver disease (eg, ascites).

7. Renal failure requiring dialysis.

8. Active pathological bleeding or increased risk of bleeding complications according to the Investigator.

9. Haemoglobin <6 g/dL from test performed at Screening (Visit 1).

10. Platelets <100 × 10^9/L from test performed at Screening (Visit 1).

11. Patient considered to be at risk of bradycardic events (eg, known sick sinus syndrome or second or third degree atrioventricular block).

12. Concomitant oral or intravenous therapy with moderate or strong CYP3A4 inhibitors, CYP3A4 substrates with narrow therapeutic indices, or strong CYP3A4 inducers that have not been stopped at least 5 half-lives before dose administration.

13. Patient breastfed by mother who is under treatment of strong CYP3A4 inhibitors,

14. Active untreated malaria. Patients with suspected malaria at Screening (Visit 1) will be tested.

15. Surgical procedure planned to occur during the study including 5 days after ticagrelor administration.

16. Known hypersensitivity or contraindication to ticagrelor.

17. Concern for the inability of the patient or parents to comply with study procedures and/or follow-up.

18. Any condition which, in the opinion of the Investigator, would make it unsafe or unsuitable for the patient to participate in this study.

19. Previously administered ticagrelor in the present study.

20. Participation in another clinical study with an investigational medicinal product (IMP) or device during the last 30 days preceding screening/enrolment.

21. Involvement of member of patient's family in planning and/or conduct of the study (applies to both AstraZeneca personnel and personnel at study centre).

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Ticagrelor
Patients will receive a single dose of ticagrelor

Locations

Country	Name	City	State
Belgium	Research Site	Edegem
Italy	Research Site	Genova
Kenya	Research Site	Kisumu
Kenya	Research Site	Nairobi
Lebanon	Research Site	Beirut
Lebanon	Research Site	Tripoli
Spain	Research Site	Madrid
United Kingdom	Research Site	London

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

Belgium,  Italy,  Kenya,  Lebanon,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Plasma Concentration (Cmax) of Ticagrelor	This measure is obtained from observed plasma concentrations	1,2,4,6 hours post dose
Primary	Area under plasma concentration curve	This measure is obtained from the population PK analysis	1,2,4,6 hours post dose
Primary	CL/F (Oral clearance)	This measure is obtained from the population PK analysis.	1,2,4,6 hours post dose
Secondary	Peak Plasma Concentration (Cmax) for active metabolite (AR-C124910XX)		1,2,4,6 hours post dose
Secondary	Area under plasma concentration curve		1,2,4,6 hours post dose
Secondary	Assessment of ticagrelor suspension for palatability	Questionnaire with one five-options question reflecting different degrees of patients willingness to swallow, from "swallowed without problem" to "vomited up medication".	Day 1, single timepoint assessment

External Links

•   Study results information posted to AstraZeneca Cinical Trials Webiste